trastuzumab deruxtecan,ruxolitinib
novartis,daiichi sankyo,incyte,astrazeneca
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'rectal', 'trastuzumab deruxtecan', 'rux,(-crux),(-trux)', 'crcsm', 'colorectal']
trastuzumab deruxtecan elicits responses in patients with her2-positive metastatic colorectal cancer, a phase 2 study presented at asco 2023 suggests. #asco23 #crcsm 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.